Scientists have created a new test for multiple KMT2A-fusions in acute myeloid leukaemia (AML) to help guide tailored treatment. The test highlights any residual disease present during treatment, the developers say. They say current methods are ei...
6 months ago
The UK is to have access to its first gene editing therapy for sickle cell disease and β-thalassaemia, it has been announced. The CRISPR-based treatment, Casgevy, gained a licence from the Medicines and Healthcare products Regulatory Agency (MHRA)...
6 months ago